Gene therapies advance towards finish line

Nature Reviews Drug Discovery

Volumn 10, Issue 10, 2011, Pages 719-720

  Mullard, Asher ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALIPOGENE TIPARVOVEC; LENTIVIRUS VECTOR; ORNITHINE CARBAMOYLTRANSFERASE; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ADVERSE OUTCOME; ARTICLE; BETA THALASSEMIA; BIOREACTOR; CANCER RISK; CARCINOGENICITY; CELL BASED GENE THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; FOLLOW UP; GENE; GENE TARGETING; GENE THERAPY; GENE VECTOR; HIGH RISK PATIENT; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE RESPONSE; IMMUNOGENICITY; LEBER CONGENITAL AMAUROSIS; LEUKEMIA; MONOGENIC DISORDER; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; POPULATION RESEARCH; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RISK ASSESSMENT; RISK REDUCTION; RPE65 GENE; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOGENETIC PHENOMENA; RARE DISEASES;

EID: 80053512134     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3572     Document Type: Article

References (9)

1. Maguire, A. M. et al. N. Engl. J. Med. 358, 2240-2248 (2008).
2. Cavazzana-Calvo, M. et al. Nature 467, 318-322 (2010).
3. Boztug, K. et al. N. Engl. J. Med. 363, 1918-1927 (2010).
4. Porter, D. L. et al. N. Engl. J. Med. 365, 725-733 (2011).
5. Aiuti, A. et al. N. Engl. J. Med. 360, 447-458 (2009).
6. Gaspar, H. B. et al. Sci. Transl. Med. 3, 97ra80 (2011).
7. Gaspar, H. B. et al. Sci. Transl. Med. 3, 97ra79 (2011).
8. Cavazzana-Calvo, M. et al. Science 288, 669-672 (2000).
9. Kay, M. A. Nature Rev. Genet. 12, 316-328 (2011).